Treatment of bacillus calmette-guérin refractory non-muscle invasive bladder cancer

Archivos Espanoles de Urologia

Volumn 66, Issue 9, 2013, Pages 833-840

  Turker, Polat ^a   Turkeri, Levent ^b  

^a NAMIK KEMAL UNIVERSITY   (Turkey)

^b Marmara University Faculty of Medicine   (Italy)

Author keywords

BCG failure; Itravesical therapy; Non muscle invasive bladder cancer

Indexed keywords

ANTINEOPLASTIC AGENT; BCG VACCINE; IMMUNOLOGICAL ADJUVANT;

ARTICLE; BLADDER TUMOR; CYSTECTOMY; DRUG RESISTANCE; HUMAN; IMMUNOTHERAPY; INTRAVESICAL DRUG ADMINISTRATION; TUMOR RECURRENCE; UROLOGIC SURGERY;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRAVESICAL; ANTINEOPLASTIC AGENTS; BCG VACCINE; CYSTECTOMY; DRUG RESISTANCE; HUMANS; IMMUNOTHERAPY; NEOPLASM RECURRENCE, LOCAL; URINARY BLADDER NEOPLASMS; UROLOGIC SURGICAL PROCEDURES;

EID: 84887503110     PISSN: 00040614     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (58)

1. Ferlay J, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer, 2010. 127(12): P. 2893-917.
2. Ro J.Y, G.A. Staerkel, and A.G. Ayala, Cytologic and histologic features of superficial bladder cancer. Urol Clin North Am, 1992. 19(3): P. 435-53.
3. Herr, H.W., Tumor progression and survival of patients with high grade, noninvasive papillary (TaG3) bladder tumors: 15-Year outcome. J Urol, 2000. 163(1): P. 60-1; discussion 61-2.
4. Lamm, D.L., Carcinoma in situ. Urol Clin North Am, 1992. 19(3): P. 499-508.
5. Mo, L., et al., Hyperactivation of Ha-Ras oncogene, but not Ink4a/Arf deficiency, triggers bladder tumorigenesis. J Clin Invest, 2007. 117(2): P. 314-25.
6. Nadler, R.B., et al., Durability of the tumor-Free response for intravesical bacillus Calmette-Guerin therapy. J Urol, 1994. 152(2 Pt 1): P. 367-73.
7. Lamm, D.L., et al., A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guerin for transitional-Cell carcinoma of the bladder. N Engl J Med, 1991. 325(17): P. 1205-9.
8. Solsona, E., et al., The 3-Month clinical response to intravesical therapy as a predictive factor for progression in patients with high risk superficial bladder cancer. J Urol, 2000. 164(3 Pt 1): P. 685-9.
9. Van Gils-Gielen, R.J., et al., Risk factors in carcinoma in situ of the urinary bladder. Dutch South East Cooperative Urological Group. Urology, 1995. 45(4): P. 581-6.
10. Thalmann, G.N., et al., Primary T1G3 bladder cancer: Organ preserving approach or immediate cystectomy J Urol, 2004. 172(1): P. 70-5.
11. Babjuk, M., et al., EAU guidelines on non-Muscle-Invasive urothelial carcinoma of the bladder, the 2011 update. Eur Urol, 2011. 59(6): P. 997-1008.
12. Suttmann, H., et al., Mechanisms of bacillus Calmette-Guerin mediated natural killer cell activation. J Urol, 2004. 172(4 Pt 1): P. 1490-5.
13. Zlotta, A.R., N.E. Fleshner, and M.A. Jewett, The management of BCG failure in non-Muscle-Invasive bladder cancer: An update. Can Urol Assoc J, 2009. 3(6 Suppl 4): P. S199-205.
14. Bohle, A., D. Jocham, and P.R. Bock, Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: A formal meta-Analysis of comparative studies on recurrence and toxicity. J Urol, 2003. 169(1): P. 90-5.
15. Babjuk, M., et al., EAU Guidelines on Non-Muscle-Invasive Urothelial Carcinoma of the Bladder: Update 2013. Eur Urol.
16. Herr, H.W. and G. Dalbagni, Defining bacillus Calmette-Guerin refractory superficial bladder tumors. J Urol, 2003. 169(5): P. 1706-8.
17. Palou, J., et al., Recurrence at three months and high-Grade recurrence as prognostic factor of progression in multivariate analysis of T1G2 bladder tumors. Urology, 2009. 73(6): P. 1313-7.
18. Saint, F., et al., Do prognostic parameters of remission versus relapse after Bacillus Calmette-Guerin (BCG) immunotherapy exist. analysis of a quarter century of literature. Eur Urol, 2003. 43(4): P. 351-60; discussion 360-1.
19. Fernandez-Gomez, J., et al., Prognostic factors in patients with non-Muscle-Invasive bladder cancer treated with bacillus Calmette-Guerin: Multivariate analysis of data from four randomized CUETO trials. Eur Urol, 2008. 53(5): P. 992-1001.
20. Gontero, P., et al., Prognostic factors and risk groups in T1G3 patients initially treated with BCG: Results of a multicenter retrospective series in 2530 patients The Journal of Urology, 2013 AUA annual meeting program abstracts, 2013. 189(4 (supplement)): P. 1697.
21. Luo, Y., et al., IFN-Alpha 2B enhances Th1 cytokine responses in bladder cancer patients receiving Mycobacterium bovis bacillus Calmette-Guerin immunotherapy. J Immunol, 1999. 162(4): P. 2399-405.
22. ODonnell, M.A., J. Krohn, and W.C. DeWolf, Salvage intravesical therapy with interferon-Alpha 2b plus low dose bacillus Calmette-Guerin is effective in patients with superficial bladder cancer in whom bacillus Calmette-Guerin alone previously failed. J Urol, 2001. 166(4): P. 1300-4, discussion 1304-5.
23. Joudi, F.N., B.J. Smith, and M.A. ODonnell, Final results from a national multicenter phase II trial of combination bacillus Calmette-Guerin plus interferon alpha-2B for reducing recurrence of superficial bladder cancer. Urol Oncol, 2006. 24(4): P. 344-8.
24. Gallagher, B.L., et al., Impact of previous bacille Calmette-Guerin failure pattern on subsequent response to bacille Calmette-Guerin plus interferon intravesical therapy. Urology, 2008. 71(2): P. 297-301.
25. Rosevear, H.M., et al., Factors affecting response to bacillus Calmette-Guerin plus interferon for urothelial carcinoma in situ. J Urol, 2011. 186(3): P. 817-23.
26. Malmstrom, P.U., et al., 5-Year followup of a randomized prospective study comparing mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma. Swedish-Norwegian Bladder Cancer Study Group. J Urol, 1999. 161(4): P. 1124-7.
27. Plunkett, W., et al., Gemcitabine: Metabolism, mechanisms of action, and self-Potentiation. Semin Oncol, 1995. 22(4 Suppl 11): P. 3-10.
28. Dalbagni, G., et al., Phase II trial of intravesical gemcitabine in bacille Calmette-Guerin-Refractory transitional cell carcinoma of the bladder. J Clin Oncol, 2006. 24(18): P. 2729-34.
29. Sternberg, I.A., et al., Intravesical gemcitabine for high-Risk non-Muscle-Invasive bladder cancer after bacillus Calmette-Guerin treatment failure. Journal of Urology® , doi: 10.1016/j.juro.2013.04.120., 2013.
30. Di Lorenzo, G., et al., Gemcitabine versus bacille Calmette-Guerin after initial bacille Calmette-Guerin failure in non-Muscle-Invasive bladder cancer: A multicenter prospective randomized trial. Cancer, 2010. 116(8): P. 1893-900.
31. Skinner, E.C., et al., SWOG S0353: Phase II Trial of Intravesical Gemcitabine in Patients with Nonmuscle Invasive Bladder Cancer who had Recurrence after at Least 2 Prior Courses of Intravesical Bacillus Calmette-Guerin. J Urol, 2013.
32. Calabro, F. and C.N. Sternberg, New drugs and new approaches for the treatment of metastatic urothelial cancer. World J Urol, 2002. 20(3): P. 158-66.
33. McKiernan, J.M., et al., Phase I trial of intravesical docetaxel in the management of superficial bladder cancer refractory to standard intravesical therapy. J Clin Oncol, 2006. 24(19): P. 3075-80.
34. Barlow, L., J.M. McKiernan, and M.C. Benson, Long-Term survival outcomes with intravesical docetaxel for recurrent nonmuscle invasive bladder cancer after previous bacillus Calmette-Guerin therapy. J Urol, 2013. 189(3): P. 834-9.
35. McKiernan, J.M., et al., A phase I trial of intravesical nanoparticle albumin-Bound paclitaxel in the treatment of bacillus Calmette-Guerin refractory nonmuscle invasive bladder cancer. J Urol, 2011. 186(2): P. 448-51.
36. Holder, D., et al., Phase I/II trial of intravesical nanoparticle albumin-Bound Paclitaxel for the treatment of BCG refractory non-Muscle invasive Transitional Cell Carcinoma The Journal of Urology, 2013 AUA annual meeting program abstracts, 2013. 189(4 supp.): P. 1696.
37. Grossman, H.B., et al., Bacillus calmette-Guerin failures and beyond: Contemporary management of non-Muscle-Invasive bladder cancer. Rev Urol, 2008. 10(4): P. 281-9.
38. Steinberg, G., et al., Efficacy and safety of valrubicin for the treatment of Bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. The Valrubicin Study Group. J Urol, 2000. 163(3): P. 761-7.
39. Dinney, C.P., R.E. Greenberg, and G.D. Steinberg, Intravesical valrubicin in patients with bladder carcinoma in situ and contraindication to or failure after bacillus Calmette-Guerin. Urol Oncol, 2012.
40. Paroni, R., et al., Effect of local hyperthermia of the bladder on mitomycin C pharmacokinetics during intravesical chemotherapy for the treatment of superficial transitional cell carcinoma. Br J Clin Pharmacol, 2001. 52(3): P. 273-8.
41. Van Der Heijden, A.G., et al., The effect of hyperthermia on mitomycin-C induced cytotoxicity in four human bladder cancer cell lines. Eur Urol, 2004. 46(5): P. 670-4.
42. Van Der Heijden, A.G., et al., Effect of hyperthermia on the cytotoxicity of 4 chemotherapeutic agents currently used for the treatment of transitional cell carcinoma of the bladder: An in vitro study. J Urol, 2005. 173(4): P. 1375-80.
43. Colombo, R., et al., Combination of intravesical chemotherapy and hyperthermia for the treatment of superficial bladder cancer: Preliminary clinical experience. Crit Rev Oncol Hematol, 2003. 47(2): P. 127-39. 839
44. Van Der Heijden, A.G., et al., Preliminary European results of local microwave hyperthermia and chemotherapy treatment in intermediate or high risk superficial transitional cell carcinoma of the bladder. Eur Urol, 2004. 46(1): P. 65-71; discussion 71-2.
45. Nativ, O., et al., Combined thermo-Chemotherapy for recurrent bladder cancer after bacillus Calmette-Guerin. J Urol, 2009. 182(4): P. 1313-7.
46. Lammers, R.J., et al., The role of a combined regimen with intravesical chemotherapy and hyperthermia in the management of non-Muscle-Invasive bladder cancer: A systematic review. Eur Urol, 2011. 60(1): P. 81-93.
47. Brausi, M., et al., Intravesical electromotive administration of drugs for treatment of superficial bladder cancer: A comparative Phase II study. Urology, 1998. 51(3): P. 506-9.
48. Di Stasi, S.M., et al., Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk superficial bladder cancer: A prospective randomized study. J Urol, 2003. 170(3): P. 777-82.
49. Di Stasi, S.M., et al., Sequential BCG and electromotive mitomycin versus BCG alone for high-Risk superficial bladder cancer: A randomised controlled trial. Lancet Oncol, 2006. 7(1): P. 43-51.
50. Waidelich, R., et al., Clinical experience with 5-Aminolevulinic acid and photodynamic therapy for refractory superficial bladder cancer. J Urol, 2001. 165(6 Pt 1): P. 1904-7.
51. Lange, N., et al., Photodetection of early human bladder cancer based on the fluorescence of 5-Aminolaevulinic acid hexylester-Induced protoporphyrin IX: A pilot study. Br J Cancer, 1999. 80(1-2): P. 185-93.
52. Bader, M.J., et al., Photodynamic Therapy of Bladder Cancer -A Phase I Study Using Hexaminolevulinate (HAL). Urol Oncol, 2012.
53. Lee, J.Y., et al., Efficacy and Safety of Photodynamic Therapy for Recurrent, High Grade Nonmuscle Invasive Bladder Cancer Refractory or Intolerant to Bacille Calmette-Guerin Immunotherapy. J Urol, 2013.
54. Herr, H.W. and P.C. Sogani, Does early cystectomy improve the survival of patients with high risk superficial bladder tumors J Urol, 2001. 166(4): P. 1296-9.
55. Gupta, A., et al., Outcomes of patients with clinical T1 grade 3 urothelial cell bladder carcinoma treated with radical cystectomy. Urology, 2008. 71(2): P. 302-7.
56. Turker, P., et al., Upstaging of urothelial cancer at the time of radical cystectomy: Factors associated with upstaging and its effect on outcome. BJU Int, 2012. 110(6): P. 804-11.
57. Svatek, R.S., et al., Discrepancy between clinical and pathological stage: External validation of the impact on prognosis in an international radical cystectomy cohort. BJU Int, 2011. 107(6): P. 898-904.
58. Freeman, J.A., et al., Radical cystectomy for high risk patients with superficial bladder cancer in the era of orthotopic urinary reconstruction. Cancer, 1995. 76(5): P. 833-9.